Sanofi re­ports sales growth amid Dupix­en­t's Chi­na launch, but re­veals PDU­FA de­lay in Pompe dis­ease pro­gram

Sanofi re­leased its first quar­ter earn­ings re­port Wednes­day, and while the com­pa­ny saw pos­i­tive news re­gard­ing growth and sales — par­tic­u­lar­ly in Chi­na — they al­so re­vealed for the first time a de­lay in one of their lead Phase III pro­grams.

The French phar­ma’s Pompe dis­ease pro­gram aval­glu­cosi­dase al­fa saw its PDU­FA date pushed back by three months, from May 18 to Aug. 18, Sanofi not­ed in its in­vestor pre­sen­ta­tion. No rea­son was giv­en for the move, and End­points News has reached out for com­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER